Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 8/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26024799 | 0.93 | SSTR3 (0.47) | SSTR3OPRK1SIRT2SIRT1SIRT3 | |
| SCHEMBL26025959 | 0.85 | OPRK1 (0.49) | SSTR3OPRK1SIRT2SIRT1SIRT3 | |
| SCHEMBL29649537 | 0.85 | SSTR3 (0.42) | SSTR3OPRK1SIRT2SIRT1SIRT3 | |
| SCHEMBL26015648 | 0.81 | PTPN1 (0.44) | SSTR3SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26015649 | 0.81 | SPHK1 (0.45) | — | |
| SCHEMBL19479881 | 0.79 | OPRK1 (0.45) | OPRK1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26015583 | 0.78 | SIRT2 (0.45) | OPRK1SIRT2SIRT1SIRT3SIRT5 | |
| Hydrochloric Acid SCHEMBL6290469 | 0.77 | LTA4H (0.51) | SSTR3OPRK1 | |
| SCHEMBL26015651 | 0.77 | TLR2 (0.44) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL8515919 | 0.76 | OPRD1 (0.40) | SSTR3OPRK1SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SSTR3 3591/4885OPRK1 4393/4885SIRT2 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.